Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies

Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis

(2020) Magid Awadalla et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment

(2020) Nicolas Palaskas et al.   Journal of the American Heart Association

Heart-Specific Immune Responses in an Animal Model of AutoimmuneRelated Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation

(2020) Mariella Bockstahler et al.   CIRCULATION

Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice

(2020) Kenjiro Tsuruoka et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling

(2020) Wenzheng Xia et al.   Cell Death & Disease

Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque

(2020) Zsofia D. Drobni et al.   CIRCULATION

A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention

(2020) Spencer C Wei et al.   Cancer Discovery

Cardiovascular toxicities associated with immune checkpoint inhibitors

(2019) Jiun-Ruey Hu et al.   CARDIOVASCULAR RESEARCH

Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity—From Case Report to Mouse Model Validation

(2019) Shin-Yi Liu et al.   Cancers

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study

(2019) Alice Tison et al.   Arthritis & Rheumatology

Tagged cine magnetic resonance imaging to quantify regional mechanical changes after acute myocardial infarction

(2019) Badri Karthikeyan et al.   MAGNETIC RESONANCE IMAGING

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management

(2019) Yu-Wen Zhou et al.   Frontiers in Pharmacology

Mechanisms regulating PD-L1 expression on tumor and immune cells

(2019) Shuming Chen et al.   Journal for ImmunoTherapy of Cancer

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

(2018) Xuexiang Du et al.   CELL RESEARCH

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity

(2018) Nicolas Martinez-Calle et al.   HAEMATOLOGICA

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

(2018) Giulia C. Leonardi et al.   JOURNAL OF CLINICAL ONCOLOGY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes

(2018) Shisuo Du et al.   Journal of Thoracic Oncology

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

(2018) Javid J Moslehi et al.   LANCET

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non‐Small Cell Lung Cancer Patients

(2018) Matteo Sarocchi et al.   ONCOLOGIST

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity

(2018) Nicolas Martinez-Calle et al.   HAEMATOLOGICA

Mechanisms of Resistance to Immune Checkpoint Blockade

(2018) David Liu et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Immune checkpoint inhibitors and cardiovascular toxicity

(2018) Alexander R Lyon et al.   LANCET ONCOLOGY

Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues

(2017) Carey J. Myers et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

(2017) Narek Shaverdian et al.   LANCET ONCOLOGY

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

(2016) A. M. Menzies et al.   ANNALS OF ONCOLOGY

Cancer immunotherapy: the beginning of the end of cancer?

(2016) Sofia Farkona et al.   BMC Medicine

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer

(2016) Jing Liu et al.   CANCER RESEARCH

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

FDA approves first immunotherapy combo

(2015) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms

(2015) Neil K. Taunk et al.   Frontiers in Oncology

Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153

(2015) Babak Baban et al.   PLoS One

Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice

(2014) J. A. Lucas et al.   JOURNAL OF IMMUNOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 deficiency results in the development of fatal myocarditis in MRL mice

(2010) Jian Wang et al.   INTERNATIONAL IMMUNOLOGY

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

(2009) Y. Lee et al.   BLOOD